Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

NCT00077779 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00077779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00077779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Lead sponsor
Abbott
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2003
Completion date
Not reported
Enrollment
854 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease